Clinical Implications of Recent Cholesterol Lowering Trials for the Secondary Prevention of Coronary Heart DiseaseByRobert A. Vogel, MDMarch 1st 1997
Converting Clinical Lipid Trials into the Practical Management of High-Risk Patients: New NECP Thoughts on Treating CHD PatientsByScott Grundy, MD, PhDMarch 1st 1997
Review of the NIH Post-CABG Study and Future Advances in HMG-CoA TherapyByDavid B. Hunninghake, MDMarch 1st 1997
Accuracy of Lipid Profiles in the Hospital Setting: Impact on the Initiation of Cholesterol-Lowering TherapyByLeonard Keilson, MD, MPHMarch 1st 1997
The Undertreatment Problem: Identifying Barriers to TreatmentByR. Wayne Alexander, MD, PhDMarch 1st 1997
Practical Disease Management as a Solution to the Undertreatment ProblemByRichard C. Pasternak, MDMarch 1st 1997
Major Clinical Trials: Pharmacologic Therapy in Higher Risk PatientsBySidney C. Smith, Jr, MDMarch 1st 1997
Lack of Intensive Treatment of CHD Risk Factors: Could the Physician Be the Most Important Risk Factor?ByRobert A. Vogel, MDMarch 1st 1997
Risk Factor Management and the Interventionalist: Treating the Patient, Not Just the LesionByJeffrey J. Popma, MDMarch 1st 1997
Lessons Learned from Lipid-Lowering Trials That Have Included WomenByThomas A. Pearson, MD, PhD,Tatu A. Miettinen, MDMarch 1st 1997
Identifying Women at Risk and Providing Protective MeasuresByMillicent Higgins, MD,Elizabeth Barrett-Connor, MDMarch 1st 1997
Strategies to Enhance Risk Factor Management in Clinical PracticeByNancy Houston-Miller, RN, BSNMarch 1st 1997
Safety and Tolerability of Lipid-Lowering Drugs After Heart Transplantation: The Heart Transplant Lipid RegistryByChristie M. Ballantyne, MDMarch 1st 1997
Possible Use of Ultrafast CT of Coronaries to Make Decisions in Hyperlipidemic PatientsByLinda L. Demer, MD, PhDMarch 1st 1997
